title: Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. vrede001@mc.duke.edu
authors.forename: James J
authors.initials: JJ
authors.lastname: Vredenburgh
authors.forename: Annick
authors.initials: A
authors.lastname: Desjardins
authors.forename: John P
authors.initials: JP
authors.lastname: Kirkpatrick
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Katherine B
authors.initials: KB
authors.lastname: Peters
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.forename: Jennifer
authors.initials: J
authors.lastname: Marcello
authors.forename: Leighann
authors.initials: L
authors.lastname: Bailey
authors.forename: Stevie
authors.initials: S
authors.lastname: Threatt
authors.forename: John
authors.initials: J
authors.lastname: Sampson
authors.forename: Allan
authors.initials: A
authors.lastname: Friedman
authors.forename: Henry S
authors.initials: HS
authors.lastname: Friedman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D059248:Chemoradiotherapy / Q000379:methods*; D003399:Craniotomy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005260:Female; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D000077204:Temozolomide; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D005938:Glucocorticoids; D000068258:Bevacizumab; D000077146:Irinotecan; D003606:Dacarbazine; D003907:Dexamethasone; D002166:Camptothecin; D000077204:Temozolomide